{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-148822","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2021-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.068771+00:00","generated_at":"2026-06-28T01:36:12.343488+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Altimmune appoints Richard Eisenstadt as CFO effective Dec 31, 2021","bullets":["William Brown resigns as CFO effective Dec 31, 2021 to pursue other opportunities; no disagreement.","Richard Eisenstadt appointed CFO effective Dec 31; annual salary $425,000, target bonus 40%, signing bonus $120,000.","Eisenstadt receives 150,000 stock options and 50,000 RSUs; options vest 25% at one year, balance over 36 months.","Eisenstadt previously CFO at Aytu BioPharma and Neos Therapeutics; raised over $340M in financings."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-148822","json":"https://secwatch.observer/filing/0001104659-21-148822.json","markdown":"https://secwatch.observer/filing/0001104659-21-148822.md","text":"https://secwatch.observer/filing/0001104659-21-148822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000110465921148822/0001104659-21-148822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000110465921148822/tm2135141d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T01:36:12.343488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e0515dd5a","claim":"William Brown resigned as Chief Financial Officer at Altimmune, Inc..","evidence_excerpt":"William Brown, the Chief Financial Officer, principal accounting officer and principal financial officer of Altimmune, Inc. (the “Company”), submitted notice to the Company’s Board of Directors (the “Board”) of his resignation, effective as of December 31, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465921148822/0001104659-21-148822-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"94a33686cf","claim":"Richard I. Eisenstadt was appointed as Chief Financial Officer at Altimmune, Inc..","evidence_excerpt":"the Company issued a press release announcing the decision of the Board to appoint Mr. Richard I. Eisenstadt as the Company’s Chief Financial Officer (“CFO”), effective December 31, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465921148822/0001104659-21-148822-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}